Literature DB >> 23596138

Characterizing short stature by insulin-like growth factor axis status and genetic associations: results from the prospective, cross-sectional, epidemiogenetic EPIGROW study.

Peter Clayton1, Mireille Bonnemaire, Pascale Dutailly, Pascal Maisonobe, Laurent Naudin, Emmanuel Pham, Zhidong Zhang, Andrew Grupe, Arunthathi Thiagalingam, Patrice Denèfle.   

Abstract

CONTEXT: Serum IGF-I levels are often low in patients with short stature (SS) without defined etiology. Hence, genetic investigations have focused on the GH-IGF-I axis.
OBJECTIVE: Our objectives were to characterize IGF-I axis status and search for a broader range of genetic associations in children with SS and normal GH. DESIGN AND
SETTING: We conducted a prospective, cross-sectional, epidemiogenetic case-control study in 9 European countries (2008-2010). PARTICIPANTS: Children (n = 275) aged ≥2 years with SS without defined etiology (≤-2.5 height SD score [SDS]) and ≥1 peak GH ≥7 μg/L) were recruited.
METHODS: Serum IGF-I, IGF-binding protein-3 (IGFBP-3), and acid-labile subunit (ALS) levels were measured in a central laboratory. Candidate gene exome sequencing was performed in this cohort and ethnicity-matched controls.
RESULTS: Serum IGF-I, IGFBP-3, and ALS levels were highly correlated, but there was a discrepancy between prevalence of IGF-I, IGFBP-3, and ALS deficiencies (53%, 30%, and 0.8%, respectively). An insertion-deletion (Indel) on the IGF1 gene (P = 1.2 × 10(-5), Bonferroni-corrected; case vs control frequency: 0.04 vs 0.112), an Indel on NFKB1 (P = 1.36 × 10(-10); case vs control frequency: 0.464 vs 0.272), and 2 single-nucleotide polymorphisms on ZBTB38 (P < 2.3 × 10(-6)) were associated with SS. At P < 10(-4), single-nucleotide polymorphisms on genes related to protein kinase regulation, MAPK, and Fanconi pathways were also associated with SS.
CONCLUSIONS: IGF-I deficiency is a common feature in SS without defined etiology; an Indel in the IGF1 gene was associated with SS. However, genes involved in transcriptional regulation (NFKB1 and ZBTB38) and growth factor signaling were also associated, providing further candidates for genetic investigations on individual patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23596138     DOI: 10.1210/jc.2012-4283

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  10 in total

Review 1.  Genetic evaluation of short stature.

Authors:  Andrew Dauber; Ron G Rosenfeld; Joel N Hirschhorn
Journal:  J Clin Endocrinol Metab       Date:  2014-06-10       Impact factor: 5.958

Review 2.  Nonclassical GH Insensitivity: Characterization of Mild Abnormalities of GH Action.

Authors:  Helen L Storr; Sumana Chatterjee; Louise A Metherell; Corinne Foley; Ron G Rosenfeld; Philippe F Backeljauw; Andrew Dauber; Martin O Savage; Vivian Hwa
Journal:  Endocr Rev       Date:  2019-04-01       Impact factor: 19.871

3.  Differentially methylated CpGs in response to growth hormone administration in children with idiopathic short stature.

Authors:  Xiaojian Shao; Catherine Le Stunff; Warren Cheung; Tony Kwan; Mark Lathrop; Tomi Pastinen; Pierre Bougnères
Journal:  Clin Epigenetics       Date:  2022-05-18       Impact factor: 7.259

4.  The psychometric evaluation of the quality of life in short stature youth (QoLISSY) instrument for German children born small for gestational age.

Authors:  R Sommer; J Blömeke; M Bullinger; J Quitmann
Journal:  J Endocrinol Invest       Date:  2018-02-17       Impact factor: 4.256

Review 5.  Minireview: mechanisms of growth hormone-mediated gene regulation.

Authors:  Dennis J Chia
Journal:  Mol Endocrinol       Date:  2014-05-13

6.  Towards identification of molecular mechanisms of short stature.

Authors:  Lindsey A Waldman; Dennis J Chia
Journal:  Int J Pediatr Endocrinol       Date:  2013-11-20

7.  Depletion of ZBTB38 potentiates the effects of DNA demethylating agents in cancer cells via CDKN1C mRNA up-regulation.

Authors:  Claire Marchal; Maud de Dieuleveult; Claude Saint-Ruf; Nadège Guinot; Laure Ferry; Sara T Olalla Saad; Mariana Lazarini; Pierre-Antoine Defossez; Benoit Miotto
Journal:  Oncogenesis       Date:  2018-10-11       Impact factor: 7.485

8.  Role of ZBTB38 Genotype and Expression in Growth and Response to Recombinant Human Growth Hormone Treatment.

Authors:  Samuel Parsons; Adam Stevens; Andrew Whatmore; Peter E Clayton; Philip G Murray
Journal:  J Endocr Soc       Date:  2022-01-18

9.  Novel Mutations and Genes That Impact on Growth in Short Stature of Undefined Aetiology: The EPIGROW Study.

Authors:  Reena Perchard; Philip George Murray; Antony Payton; Georgina Lee Highton; Andrew Whatmore; Peter Ellis Clayton
Journal:  J Endocr Soc       Date:  2020-09-10

10.  ZBTB38 suppresses prostate cancer cell proliferation and migration via directly promoting DKK1 expression.

Authors:  Guanxiong Ding; Wei Lu; Qing Zhang; Kai Li; Huihui Zhou; Fei Wang; Chunchun Zhao; Caibin Fan; Jianqing Wang
Journal:  Cell Death Dis       Date:  2021-10-25       Impact factor: 8.469

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.